Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

References

• KohAHExpert PCV PanelChenLJPolypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatmentRetina201333468671623455233
   PubMed Web of Science ®Google Scholar
• Japanese Study Group of Polypoidal Choroidal VasculopathyCriteria for diagnosis of polypoidal choroidal vasculopathyNippon Ganka Gakkai Zasshi2005109741716050460
   PubMedGoogle Scholar
• TerasakiHMiyakeYSuzukiTNakamuraMNagasakaTPolypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlationBr J Ophthalmol200286332132711864892
   PubMed Web of Science ®Google Scholar
• YuzawaMPolypoidal choroidal vasculopathyNihon Ganka Gakkai Zasshi2012116200231 discussion 23222568102
   PubMedGoogle Scholar
• FanQCheungCMGChenLJShared genetic variants for polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration in East AsiansJ Hum Genet201762121049105528835638
   PubMed Web of Science ®Google Scholar
• MaLLiZLiuKAssociation of genetic variants with polypoidal choroidal vasculopathy: a systematic review and updated meta-analysisOphthalmology201512291854186526081444
   PubMed Web of Science ®Google Scholar
• NishiguchiKMYasumaTRTomidaDC9-R95X polymorphism in patients with neovascular age-related macular degenerationInvest Ophthalmol Vis Sci201253150851222190594
   PubMed Web of Science ®Google Scholar
• HondaSMatsumiyaWNegiAPolypoidal choroidal vasculopathy: clinical features and genetic predispositionOphthalmologica20142312597424280967
   PubMed Web of Science ®Google Scholar
• WongRLLaiTYPolypoidal choroidal vasculopathy: an update on therapeutic approachesJ Ophthalmic Vis Res20138435924653824
   PubMedGoogle Scholar
• KimJHChangYSLeeDWKimCGKimJWQuantification of retinal changes after resolution of submacular hemorrhage secondary to polypoidal choroidal vasculopathyJpn J Ophthalmol2018621546229188462
   PubMed Web of Science ®Google Scholar
• Akagi-KurashigeYTsujikawaAYuzawaMA 5-year multi-center prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 studyJpn J Ophthalmol201862213714329224056
   PubMed Web of Science ®Google Scholar
• KumeAOhshiroTSakuradaYKikushimaWYoneyamaSKashiwagiKTreatment patterns and health care costs for age-related macular degeneration in Japan: an analysis of national insurance claims dataOphthalmology201612361263126826927204
   PubMed Web of Science ®Google Scholar
• KawasakiRWangJJJiGJPrevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata studyOphthalmology200811581376138118222000
   PubMed Web of Science ®Google Scholar
• YasudaMKiyoharaYHataYNine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama studyOphthalmology2009116112135214019744734
   PubMed Web of Science ®Google Scholar
• TsujikawaAAkagi-KurashigeYYuzawaMBaseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 reportJpn J Ophthalmol201862212713629270814
   PubMed Web of Science ®Google Scholar
• ShoKTakahashiKYamadaHPolypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristicsArch Ophthalmol2003121101392139614557174
   PubMedGoogle Scholar
• MarukoIIidaTSaitoMNagayamaDSaitoKClinical characteristics of exudative age-related macular degeneration in Japanese patientsAm J Ophthalmol20071441152217509509
   PubMed Web of Science ®Google Scholar
• CoscasGYamashiroKCoscasFComparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imagingAm J Ophthalmol2014158230931824844973
   PubMed Web of Science ®Google Scholar
• TanoYGuidelines for PDT in JapanOphthalmology20081153585585.e6
   Web of Science ®Google Scholar
• KohALeeWKChenL-JEVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathyRetina2012321453146422426346
   PubMed Web of Science ®Google Scholar
• KohALaiTYYTakahashiKEfficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathyJAMA Ophthalmol2017135111206121328983556
   PubMed Web of Science ®Google Scholar
• TakahashiKOguraYIshibashiTShiragaFYuzawaMTreatment guidelines for age-related macular degenerationNippon Ganka Gakkai Zasshi20121161150115523379205
   PubMedGoogle Scholar
• GomiFOshimaYMoriRInitial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan StudyRetina20153581569157625830698
   PubMed Web of Science ®Google Scholar
• KurodaYYamashiroKMiyakeMFactors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort studyOphthalmology2015122112303231026271842
   PubMed Web of Science ®Google Scholar
• MatsumiyaWHondaSOtsukaKOne-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathyGraefes Arch Clin Exp Ophthalmol2017255354154827687988
   PubMed Web of Science ®Google Scholar
• SilvaRBertaALarsenMTreat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND StudyOphthalmology2018125576528893454
   PubMed Web of Science ®Google Scholar
• VorumHOlesenTKZinckJStørling HedegaardMReal world evidence of use of anti-VEGF therapy in DenmarkCurr Med Res Opin201632121943195027494692
   PubMed Web of Science ®Google Scholar
• NomuraHNakayamaTThe Japanese healthcare systemBr Med J2005331751864864916179678
   PubMed Web of Science ®Google Scholar
• GomiFSawaMWakabayashiTSasamotoYSuzukiMTsujikawaMEfficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathyAm J Ophthalmol20101501485420609707
   PubMed Web of Science ®Google Scholar
• SatoTKishiSMatsumotoHMukaiRComparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathyAm J Ophthalmol201315619510523628354
   PubMed Web of Science ®Google Scholar
• TomitaKTsujikawaAYamashiroKTreatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumabAm J Ophthalmol20121531688021907965
   PubMed Web of Science ®Google Scholar
• WongCWCheungCMGMathurRThree-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic reviewRetina2015351577159325719986
   PubMed Web of Science ®Google Scholar
• YamashitaAShiragaFShiragamiCShirakataYFujiwaraATwo-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathyAm J Ophthalmol201315519610222995028
   PubMed Web of Science ®Google Scholar
• KamedaTTsujikawaAOtaniAPolypoidal choroidal vasculopathy examined with en face optical coherence tomographyClin Exp Ophthalmol200735759660117894678
   PubMed Web of Science ®Google Scholar
• YadavSParryDGBeareNAVPearceIAPolypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in CaucasiansBr J Ophthalmol20171011013771380 bjophthalmol-2016-31007428270486
   PubMed Web of Science ®Google Scholar
• KohAPrajapatiKMacfaddenWBaseline characteristics and 1-year outcomes of treatment-naïve nAMD patients with PCV from the LUMINOUS study: ranibizumab in a real-world setting17th EURETINA CongressBarcelona, Spain7–10 September 2017 Available from: http://new.euretina.org/barcelona2017/programme/free-papers-details.asp?id=13359&day=0Accessed July 24, 2018
   Google Scholar